Intercept Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Private
- Employees
-
341
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$592M
Intercept Pharmaceuticals General Information
Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Contact Information
Website
www.interceptpharma.comCorporate Office
- 305 Madison Avenue
- Morristown, NJ 07960
- United States
Corporate Office
- 305 Madison Avenue
- Morristown, NJ 07960
- United States
Intercept Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 08-Nov-2023 | $592M | Completed | Generating Revenue | ||
| 10. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 9. 2PO | 19-Feb-2019 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 09-Oct-2015 | Completed | Generating Revenue | |||
| 7. 2PO | 18-Jun-2013 | Completed | Generating Revenue | |||
| 6. IPO | 11-Oct-2012 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 09-Aug-2012 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 25-Jan-2010 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A) | 29-Jul-2008 | $25M | $29.2M | Completed | Clinical Trials - Phase 2 | |
| 2. Early Stage VC | 04-May-2005 | $1.25M | $4.25M | Completed | Product Development |
Intercept Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 13,888,889 | $0.001000 | $0.11 | $1.8 | $1.8 | 1x | $1.8 | 9.92% |
Intercept Pharmaceuticals Comparisons
Industry
Financing
Details
Intercept Pharmaceuticals Competitors (59)
One of Intercept Pharmaceuticals’s 59 competitors is Enanta Pharmaceuticals, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals | Formerly VC-backed | Watertown, MA | ||||
| TG Therapeutics | Corporation | Morrisville, NC | ||||
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Supernus | Formerly VC-backed | Rockville, MD | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA |
Intercept Pharmaceuticals Patents
Intercept Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025250918-A1 | Novel compositions | Pending | 30-May-2024 | ||
| WO-2025240669-A1 | Crystalline forms of a farnesoid x receptor agonist | Pending | 15-May-2024 | ||
| WO-2024163640-A2 | Methods and intermediates for the preparation of bile acid derivatives | Inactive | 01-Feb-2023 | ||
| WO-2024163640-A3 | Methods and intermediates for the preparation of bile acid derivatives | Inactive | 01-Feb-2023 | ||
| WO-2024102925-A1 | Crystalline forms of a farnesoid x receptor agonist | Inactive | 11-Nov-2022 | C07J9/005 |
Intercept Pharmaceuticals Signals
Intercept Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
26.5 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Intercept Pharmaceuticals FAQs
-
When was Intercept Pharmaceuticals founded?
Intercept Pharmaceuticals was founded in 2002.
-
Where is Intercept Pharmaceuticals headquartered?
Intercept Pharmaceuticals is headquartered in Morristown, NJ.
-
What is the size of Intercept Pharmaceuticals?
Intercept Pharmaceuticals has 341 total employees.
-
What industry is Intercept Pharmaceuticals in?
Intercept Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Intercept Pharmaceuticals a private or public company?
Intercept Pharmaceuticals is a Private company.
-
What is the current valuation of Intercept Pharmaceuticals?
The current valuation of Intercept Pharmaceuticals is .
-
What is Intercept Pharmaceuticals’s current revenue?
The current revenue for Intercept Pharmaceuticals is .
-
How much funding has Intercept Pharmaceuticals raised over time?
Intercept Pharmaceuticals has raised $219M.
-
Who are Intercept Pharmaceuticals’s competitors?
Enanta Pharmaceuticals, TG Therapeutics, Pliant Therapeutics, Supernus, and Damora Therapeutics ( Drug Discovery) are some of the 59 competitors of Intercept Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process